Beste apotheek van Nederland

Pommerville P. Drug treatments for erectile dysfunction: An
update. Geriatrics and Aging 2004;7(6):10-16.
Porst H. IC351 (tadalafil, Cialis): update on clinical experience.
[Review] [12 refs]. Int J Impot Res 2002;14Suppl-64.
Porst H. Transurethral alprostadil with MUSE (medicated
urethral system for erection) vs intracavernous alprostadil--a
comparative study in 103 patients with erectile dysfunction.. Int
J Impot Res 1997;9(4):187-192.
Porst H. Phosphodiesterase type-5 inhibitors: A critical
comparative analysis. Eau Update Series 2004;2(2):56-63.
Porst H, Lungimayr G, utsch-osterreichische S T E A. [Efficacy
and tolerability of vardenafil within the time window of 6 hours
after administration and beyond. Results of a clinical study
carried out in 233 urological offices]. MMW Fortschr Med
2005;147(Suppl 1):27-32.
Potempa A J, Ulbrich E, Bernard I et al. Efficacy of vardenafil
in men with erectile dysfunction: a flexible-dose community
practice study. Eur Urol 2004;46(1):73-79.
Pradeep C, Car N, Metelko Z. Impotence in diabetic men.
Diabetol Croat 1996;25(2):61-68.
Price D. Sildenafil citrate (Viagra) efficacy in the treatment of
erectile dysfunction in patients with common concomitant
conditions. Sildenafil Study Group. Int J Clin Pract
1999;Supplement.102-103.
Price D E, Cooksey G, Jehu D et al. The management of
impotence in diabetic men by vacuum tumescence therapy.
Diabet Med 1991;8(10):964-967.
Prieto Castro R M, nglada Curado F J, Regueiro Lopez J C et al.
Treatment with sildenafil citrate in renal transplant patients with
erectile dysfunction. BJU Int 2001;88(3):241-243.
Priyadarshi S. Oral terbutaline in the management of
pharmacologically induced prolonged erection. Int J Impot Res
2004;16(5):424-426.
Pryor J. Vardenafil: update on clinical experience. [Review] [10
refs]. Int J Impot Res 2002;14Suppl-9.
Purvis K, Brekke I, Christiansen E. Determinants of satisfactory
rigidity after intracavernosal injection with prostaglandin E1 in
men with erectile failure. Int J Impot Res 1996;8(1):9-16.
Radomski S B, Herschorn S, Rangaswamy S. Topical minoxidil
in the treatment of male erectile dysfunction. Br J Urol
1994;151(5):1225-1226.
Raffaele R, Vecchio I, Giammusso B et al. Efficacy and safety
of fixed-dose oral sildenafil in the treatment of sexual
dysfunction in depressed patients with idiopathic Parkinson's
disease. Eur Urol 2002;41(4):382-386.
Raina R, Agarwal A, Allamaneni S S et al. Sildenafil
citrate and vacuum constriction device combination
enhances sexual satisfaction in erectile dysfunction
after radical prostatectomy. Urology 2005;65(2):360­
364.
Raina R, Agarwal A, Goyal K K et al. Long-term
potency after iodine-125 radiotherapy for prostate
cancer and role of sildenafil citrate. Urology
2003;62(6):1103-1108.
Raina R, Lakin M M, Agarwal A et al. Long-term
intracavernous therapy responders can potentially
switch to sildenafil citrate after radical prostatectomy.
Urology 2004;63(3):532-537.
Raina R, Lakin M M, Agarwal A et al. Efficacy and
factors associated with successful outcome of
sildenafil citrate use for erectile dysfunction after
radical prostatectomy. Urology 2004;63(5):960-966.
Raina R, Lakin M M, Agarwal A et al. Long-term
effect of sildenafil citrate on erectile dysfunction after
radical prostatectomy: 3-year follow-up. Urology
2003;62(1):110-115.
Raina R, Lakin M M, Thukral M et al. Long-term
efficacy and compliance of intracorporeal (IC)
injection for erectile dysfunction following radical
prostatectomy: SHIM (IIEF-5) analysis. Int J Impot
Res 2003;15(5):318-322.
Rajpurkar A, Dhabuwala C B. Comparison of
satisfaction rates and erectile function in patients
treated with sildenafil, intracavernous prostaglandin
E1 and penile implant surgery for erectile dysfunction
in urology practice. Br J Urol 2003;170(1):159-163.
Rakic Z, Starcevic V, Starcevic V P et al. Testosterone
treatment in men with erectile disorder and low levels
of total testosterone in serum. Arch Sex Behav
1997;26(5):495-504.
Ralph D J, Sleep D J, Perdok R J et al. Adverse events
and patient tolerability of apomorphine SL 2 and 3
mg: A cross-study analysis of phase II and III studies.
European Urology Supplements 2002;1(3):21-27.
Ramasubbu Rajamannar. Switching to moclobemide
to reverse fluoxetine-induced sexual dysfunction in
patients with depression. J Psychiatry Neurosci
1999;24(1):45-50.
Rashid A. The efficacy and safety of PDE5 inhibitors.
[Review] [30 refs]. Clin Cornerstone 2005;7(1):47-56.
Reiter W J, Schatzl G, Mark I et al.
Dehydroepiandrosterone in the treatment of erectile
dysfunction in patients with different organic
etiologies. Urol Res 2001;29(4):278-281.
D-179